The discovery of significant serum levels of IgE specific to a panel of short, unique myelin protein-derived peptides in the cohort of 26 MS patients irrespective of clinical subtype based on an author-developed radioimmunoassay suggests that autoreactive IgE against CNS target antigens may hold valuable diagnostic potential in some MS patients (80). The gene discussed is IGHE; the disease is myeloid sarcoma.